NASA: TRISH, Kubota Pharma､SS-OCT Development: Phase 1 Status
NASA TRISH: Kubota Pharmaceutical
Kubota Pharmaceutical held a development meeting with NASA, the Translational Research Institute for Space Health (TRISH), on January 30, 2020.
Swept Source-OCT (SS-OCT): Project Progress Report
Acucela Inc., a wholly owned subsidiary of the Company (Headquarters: Washington, USA), has reported on the progress of the Micro Ophthalmic Diagnostic System Swept Source-OCT (SS-OCT) project.
Presentation: NASA and TRISH
NASA presents to 15 engineers / scientists / doctors, questions and answers,
Operation demonstration of the results / prototype of Phase 1 of this project.
The comment of the project director of NASA TRISH is as follows.
Background of this joint development:
Many astronauts have been inspired by a study report stating that there is a sign of Spaceflight Associated Neuro-ocular Syndrome (SANS), which can cause visual impairment and blindness.
There is a growing demand for real-time measurement of retinal conditions during spaceflight.
What are the symptoms of SANS?
Optic disc edema,
Posterior flattening of the eyeball,
Choroidal wall,
Vitiligo on cotton,
There is a refractive error.
Recent NASA reports:
“69% of astronauts who stay in space for long periods will have SANS.”
Kubota Pharmaceutical Holdings:
The goal is to contribute to maintaining and recovering vision for those suffering from eye diseases around the world.
Link innovation to the development and commercialization of pharmaceuticals and medical devices.
Ophthalmology Solutions Company
https://www.kubotaholdings.co.jp/ir/docs/20200203_JP_NASA%20mtg_%28final%29.pdf